Abstract: A method, an apparatus, a system, and a computer program product for handling security threats in a network data processing system. A computer system determines a connection type for a connection in response to detecting the connection between a target resource in the network data processing system and a requestor. The computer system redirects the connection to a virtual resource in place of the target resource when the connection type is a threat connection, wherein the requestor originating the connection to the target resource is unable to perceive a redirection of the connection to the virtual resource. The computer system records information in the connection redirected to the virtual resource to form recorded information. The computer system adjusts a security policy for handling connections in the network data processing system using the recorded information, wherein the security threats in the network data processing system are decreased using the security policy.

Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.

Abstract: In an approach, a processor receives a first request to store a specific key to index pages of a database, wherein: the request indicates that the specific key is to be stored to a specific leaf page in a key-ordered chain of the index pages, and there is insufficient room in the specific leaf page to store the specific key. A processor determines at least one sibling leaf page of the specific leaf page in the key-ordered chain, the specific leaf page and the at least one sibling leaf page forming a first set. A processor determines that there is enough room in leaf pages of the first set to store existing keys in the leaf pages of the first set together with the specific key. A processor stores the existing keys in the leaf pages of the first set together with the specific key according to a redistribution policy.

Abstract: A method of treating cancer in a subject includes contacting an enriched population of T-cells obtained from cancer or tumor draining lymph nodes ex-vivo with: an anti-CD3 antibody, an anti-CD28 antibody, and/or functional fragments thereof, and optionally a VEGF inhibitor and/or an IL-2 receptor agonist, at amounts effective to activate and expand the T-cells and administering the activated and expanded T-cells to the subject.

Abstract: Functional verification of a new database feature is provided. A set of SQL query seeds are evolved using information contained in a knowledge map that was generated based on a real SQL query workload of an entity corresponding to a database. Real SQL queries are identified in the database that are similar to the evolved set of sample SQL query seeds. A new feature to be implemented in the database is injected into the real SQL queries that are similar to the evolved set of sample SQL query seeds. Multiple runtime access paths are generated for each of the real SQL queries injected with the new feature for output cross validation. Each of the real SQL queries injected with the new feature is run in a test environment using each of the multiple runtime access paths corresponding to a real SQL query injected with the new feature for functional verification.

Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.

Abstract: A method of treating a subject having cancer is described that includes administering a therapeutically effective amount of a ?-(1,3)-(1,4) glucan to the subject. Methods of immunostimulating in a subject by administering an effective amount of a ?-(1,3)-(1,4) glucan to the subject are also described.

Abstract: The present disclosure provides powerful technologies for the development, production, characterization, and/or use of stapled peptide compositions. Among other things, the present disclosure provides strategies for defining amino acid sequences particularly amenable or useful for stapling, as well as technologies, reagents, and systems for developing, producing, characterizing, and/or using stapled peptides having such amino acid sequences.

Abstract: A synergistic polymerization inhibitor composition, the composition having a copper salt, and a manganese salt; a copper salt or a manganese salt, and a cationic polymer; or a phenothiazine and a manganese salt. A method for inhibiting polymerization of unsaturated polymerizable monomers, the method providing adding a synergistic polymerization inhibitor composition to an methacrylic acid manufacturing system or component thereof, the composition having a copper salt, and a manganese salt; a copper salt or a manganese salt, and a cationic polymer; or a phenothiazine and a manganese salt.

Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.

Abstract: A method, network device, and computer program product for network traffic diversion are disclosed. In one embodiment, a method according to the present disclosure includes receiving a frame at a core edge node that is a member of a redundancy group (where the frame comprises network address information and a packet), and determining whether a link (to which the core edge node is communicatively coupled) is affected by a network failure. The frame was sourced by a remote core edge node that is not a member of the redundancy group, and the network address information indicates that the packet is to be forwarded via the link. In response to the link being affected by the network failure, the method further includes generating a modified frame and forwarding the modified frame to another core edge node. The generating comprises including a redirect label in the modified frame. The another core edge node is another member of the redundancy group.

Abstract: In an approach, a processor, responsive to requesting to perform a plurality of applications including a first application and a second application, determines that the first application and the second application have been performed sequentially during a previous time period. A processor, responsive to determining that the first and second applications have been performed in sequence during the previous time period, obtains, a first set of database operations associated with the first application and a second set of database operations associated with the second application. A processors, responsive to determining that the first set of database operations and the second set of database operations are free of conflict, generates an execution schedule indicating that the first application and the second application are to be performed in parallel. A processors performs the plurality of applications based on the execution schedule.

Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.

Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.

Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.

Abstract: An acoustic mesh comprising a first portion that is acoustically closed; and a second portion that surrounds the first portion and is acoustically open, wherein a surface area of the second portion is at least one percent a total surface area of the acoustic mesh.

Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.

Abstract: The disclosed technology relates to a battery utilizing an indicator to orient an unopposed portion of a cathode or anode with respect to a battery can, and a tag to generate an electromagnetic field to mitigate or eliminate an electromagnetic field generated by the unopposed portion of the cathode or anode. The battery includes a wound set of layers including a cathode, an anode, and a separator; a can housing the wound set of layers; a lid disposed atop of the can to enclose the wound set of layers within the can; and a tag coupled to the lid. An unopposed portion of the cathode or anode generates a first electromagnetic field. The tag generates a second electromagnetic field to oppose the first electromagnetic field.

Abstract: A method of treating a subject having cancer is described that includes administering a therapeutically effective amount of a ?-(1,3)-(1,4) glucan to the subject. Methods of immunostimulating in a subject by administering an effective amount of a ?-(1,3)-(1,4) glucan to the subject are also described.

Abstract: The invention provides novel potassium ion sensor conjugates for spatiotemporal visualization of ion channel and membrane transporter activities from mammalian and human cells, and compositions and methods thereof.